China’s National Medical Products Administration (NMPA) released the 102nd batch of reference drugs for generic quality consistency evaluation (GQCE), simultaneously announcing the fourth batch of delisted reference drugs. Obeticholic Acid Tablets (OCALIVA) in 5 mg and 10 mg strengths have been removed from the reference list due to post-marketing studies failing to confirm clinical benefit while demonstrating serious risks, marking a rare regulatory reversal on a previously approved innovative drug and impacting generic development pathways for the FXR agonist class.
Regulatory Action Overview
Element
Detail
Authority
National Medical Products Administration (NMPA)
Action Type
Reference drug delisting from GQCE list
Product
Obeticholic Acid Tablets (trade name: OCALIVA)
Strengths Affected
5 mg, 10 mg
Reason for Removal
Post-marketing studies: lack of confirmed benefit + serious risks demonstrated
REGENERATE interim analysis showed fibrosis improvement but mixed results; full data disappointing
Original approval rationale undermined
Market & Industry Implications
Factor
Impact
Generic Development
Chinese generic manufacturers pursuing obeticholic acid must halt; R&D investment lost
FXR Class Impact
TERN-101, cilofexor, and other FXR agonists face heightened regulatory scrutiny
Innovator Consequences
Intercept Pharmaceuticals (OCALIVA originator) faces China market access loss; global restructuring likely
NASH Pipeline
Non-FXR mechanisms (GLP-1, PPAR, THR-β) gain relative attractiveness
Regulatory Signal
NMPA demonstrates willingness to reverse prior approvals based on real-world evidence; pharmacovigilance strengthening
Competitive Landscape Shift
Mechanism
Product
Developer
Status
Post-OCALIVA Impact
FXR Agonist
OCALIVA (obeticholic acid)
Intercept
Delisted (China)
Class reputation damaged
FXR Agonist
TERN-101
Terns Pharma
Phase II
Development risk increased
THR-β Agonist
Resmetirom (Madrigal)
Madrigal
Approved (U.S.)
Relative safety advantage
GLP-1/GIP
Tirzepatide, semaglutide
Lilly, Novo
NASH Phase III
Metabolic approach gains traction
PPAR
Lanifibranor
Inventiva
Phase III
Alternative mechanism benefit
Forward‑Looking Statements This brief contains forward‑looking statements regarding regulatory precedent, class-wide safety implications, and market dynamics following the OCALIVA delisting. Actual results may differ due to ongoing safety reviews, manufacturer responses, and competitive dynamics in the NASH and cholestatic liver disease markets.-Fineline Info & Tech
By Fineline Cube